Healthcare Industry News:  Interbody fusion device 

Devices Orthopaedic Neurosurgery

 News Release - April 18, 2011

Centinel Spine(TM) Continues Record Growth in Q1, 2011

Results Demonstrate Strong Year-Over-Year Sales

NEW YORK--(Healthcare Sales & Marketing Network)-- A record 47% year-over-year sales increase for Q1, 2011 compared to the same period in 2010 was announced today by Centinel Spine, Inc. (Centinel™), innovator and a market leader in the Integrated Interbody Fusion™ spine medical device space.

Centinel’s Chairman and CEO, John J. Viscogliosi, said: “Centinel’s record setting sales pace for the third straight quarter is a testament to surgeon acceptance of our lumbar and cervical implants as a de facto industry standard for Integrated Interbody fusion devices.

“The STALIF TT™ remains a preferred product for use in anterior lumbar surgery and, when paired with STALIF C™ cervical device which offers domed and tapered device configurations, they give the STALIF™ line-up the unique ability to match a patient’s anatomy. Together these products continue to drive growth. As I noted in announcing Q4, 2010 results, we continue to expect that the balance of 2011 will produce similar, stellar results,” he added.

Centinel’s President, Michael D. Will, said: “We’ve put a strong sales and distribution system in place whose quality and expertise are commensurate with that of the combined STALIF® product line. With the expanded beta launch of our next generation lumbar device, STALIF MIDLINE™, due at the end of this month in Las Vegas at the SAS – The International Society for the Advancement of Spine Surgery - conference, we are confident of continuing, strong sales growth going forward. The equation is straightforward: great systems, plus long term clinical success, plus great people equal great results.”

About Centinel Spine, Inc.

Founded in 2008, Centinel Spine, Inc. is an innovative spinal device company committed to the design and development of simple, biomechanically sound solutions for spinal stabilization and fusion. The company is recognized as a leader in the expanding Integrated Interbody Fusion™ spinal market segment.

STALIF®, STALIF TT™, STALIF MIDLINE™, STALIF C™ and Integrated Interbody Fusion™ are registered trademarks or trademarks of Centinel Spine, Inc. in the United States and/or other countries.

For more information on Centinel Spine™:

Forward-looking statements

This news release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting Centinel Spine’s business including increased competition; the ability of Centinel Spine to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks.

Source: Centinel Spine

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.